diabetestalk.net

Medtronic Product Line

Medtronic Expands Mr-conditional Product Line With Advisa Sr Mri Surescan

Medtronic Expands Mr-conditional Product Line With Advisa Sr Mri Surescan

Medtronic expands MR-conditional product line with Advisa SR MRI SureScan DUBLIN, 25 June 2015 Medtronic plc (NYSE: MDT), today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of the Advisa SR MRI(TM) SureScan single-chamber pacemaker with the 5076 MRI lead, which allows for magnetic resonance imaging (MRI) scans positioned on any region of the body without restrictions. The new system includes the Advisa SR MRI pacemaker and a SureScan lead, which must be used together to be considered MR-conditional. MRI is the standard of care in soft tissue imaging, providing information not seen with X-ray, ultrasound, or CT scan, and without exposing patients to ionizing radiation. MRI is critical for the early detection, diagnosis and treatment of many diseases, including strokes, cancer, Alzheimer's disease, and muscle, bone and back pain - all of which are prevalent among older adults. It is estimated that 50-75 percent of patients with implantable cardiac devices will need an MRI scan over the lifetime of their device.1 Until the approval of MR-conditional pacemakers, patients with implanted devices were typically denied access to MRI procedures because of the potential for harmful interaction between the device and the MRI scanner. "MRI is a vital diagnostic tool that was not available to pacemaker patients before Medtronic released the world's first MR-conditional pacing system in 2008," said Brian Urke, vice president and general manager of the bradycardia business at Medtronic. "Through our work with clinicians, Medtronic MR-conditional pacing systems have been evaluated in four clinical studies with more than 3,600 patients, and today we offer the most extensive portfolio of MR-conditional pacing devices and leads available in the U.S Continue reading >>

Medtronic Expands Focus On Interventional Oncology With Its U.s. Launch Of Optisphere(tm) Embolization Spheres

Medtronic Expands Focus On Interventional Oncology With Its U.s. Launch Of Optisphere(tm) Embolization Spheres

Product Line Offers Unique, Resorbable Option for Patients with Hypervascular Tumors DUBLIN - April 17, 2018 - Medtronic plc (NYSE: MDT) today announced its U.S. launch of OptiSphere(TM) embolization spheres, a resorbable embolic platform designed for embolization of hypervascular tumors. OptiSphere offers patients an alternative treatment option, a resorbable embolic, with comparable results to a permanent embolic.1 Hypervascular tumors can present as malignant or benign and can be found in various anatomical structures. Physicians may choose to treat these tumors with various therapies including, but not limited to, embolization, microwave ablation, radiofrequency ablation, or cryoablation. "Medtronic continues to seek opportunities to expand the therapies we offer to patients and the physicians who treat them. With increased and better quality of care, the cancer patient population is living longer with the disease and it is important that we continue to introduce therapies that help positively impact and improve their quality of life,"said Jeff Cambra, general manager of the Pain Therapies Interventional business, which is part of the Restorative Therapies Group at Medtronic. "We consider this launch to be a win for both sides of the healthcare pathway, as OptiSphere addresses patient concerns of having permanent implanted spheres left behind while enabling physicians to offer an innovative treatment option in their facilities." OptiSphere is manufactured for Medtronic by Vascular Solutions, LLC, a subsidiary of Teleflex Incorporated (NYSE: TFX). Medtronic continues to partner with the company to further innovate the technology. OptiSphere received U.S. Food and Drug Administration (FDA) 510(k) clearance in April 2014. "Teleflex is very pleased to have Medtronic as Continue reading >>

Medtronic Business Overview - Cardiovascular

Medtronic Business Overview - Cardiovascular

CardioVascular develops products that are used throughout the heart and vascular system and those used for arrested and beating heart bypass surgery. The business markets the industrys broadest and most innovative line of heart valve products for replacement and repair, plus auto-transfusion equipment and disposable devices for handling and monitoring blood during major surgery, as well as cardiac ablation devices to treat a variety of heart conditions. The business also offers products and therapies that treat a wide range of cardiac and vascular diseases and conditions. Coronary, peripheral and neurovascular stents Stent graft systems for diseases and conditions throughout the aorta CardioVascular Offers Technology, Products, and Education The CardioVascular business is comprised of four organizations, each uniquely focused on addressing unmet needs in the treatment of cardiovascular diseases, and an education programme. Minimally invasive catheter and stent-based technologies for the treatment of coronary heart disease. Products for the treatment of heart valve disease and atrial fibrillation. These include aortic and mitral tissue valves, stentless tissue valves and some valved conduits. In addition, the trans-catheter pulmonic valve is an innovation in the treatment of some congenital conditions. A full selection of heart repair products ensures all pathologies can be treated. Products are available for the surgical treatment of atrial fibrillation. Products are available for use in both concomitant and lone AF procedures. Stent grafts for the treatment of aortic abdominal, thoracic aneurysms and peripheral artery disease Open heart and coronary bypass grafting surgical products. These products facilitate heart operations and, in some instances, allow surgeons to Continue reading >>

Medtronic | Mnopedia

Medtronic | Mnopedia

Medtronic Founder Earl Bakken and Medtronic CEO Winston Wallin with an early pacemaker model, 1986. Photographed by Jeffrey Grosscup. The Medtronic medical device company was founded in 1949 by Earl Bakken and Palmer Hermundslie. From its beginnings in a converted garage, it has grown into a multi-billion-dollar enterprise and one of Minnesotas leading businesses. In the late 1940s, electrical engineer Earl Bakken saw an opportunity for starting a business that specialized in repairing medical equipment. He discussed this idea with his brother-in-law, Palmer Hermundslie, and in 1949 they founded Medtronic. Medtronics first office was a converted boxcar garage in Minneapolis. In their first month, Bakken and Hermundslie made eight dollars for repairing one centrifuge. To make more money, they took side jobs selling medical equipment for the Sanborn Company. They also started taking contracts to build custom-ordered devices for local physicians. In 1954, Bakken began to assist with equipment during surgeries performed at the University of Minnesota. There, he met open-heart surgery pioneer Dr. C. Walton Lillehei , who in 1957 asked Bakken to create a portable, battery-powered pacemaker. Bakken created a prototype by adapting a metronome circuit from Popular Electronics and altering its voltage to match the human hearts. After this prototype was tested, Lillehei began using Medtronic pacemakers the next day. The devices became a key part of Medtronics business. After it introduced a line of new, implantable pacemakers, Medtronic saw its sales grow rapidlyfrom $180,000 in 1960 to $518,000 in 1962. The company moved into a fifteen-thousand-square-foot building and increased its staff to fifty-four people. It also expanded its product line by adding a new heart monitor and o Continue reading >>

Horizon Medical Products Named Exclusive Distributor For Medtronic's Hai Product Line For Use In The Treatment Of Primary And Colorectal Liver Cancer

Horizon Medical Products Named Exclusive Distributor For Medtronic's Hai Product Line For Use In The Treatment Of Primary And Colorectal Liver Cancer

Horizon Medical Products Named Exclusive Distributor for Medtronic's HAI Product Line for Use in the Treatment of Primary and Colorectal Liver Cancer April 23, 2003 04:00 AM Eastern Daylight Time ATLANTA--( BUSINESS WIRE )--April 23, 2003--Horizon Medical Products, Inc. (AMEX:HMP) today announced a new distribution agreement with Medtronic Inc. (NYSE:MDT). Under this agreement, Horizon has exclusive U.S. rights, commencing in June 2003, to distribute Medtronic's Hepatic Arterial Infusion (HAI) product line, including sales and case support of Medtronic's IsoMed(R) Infusion System and related products. This collaboration complements the co-promotion agreement between the two companies that began approximately one year ago. Horizon Medical will continue to promote Medtronic's SynchroMed(R) product line for cancer pain applications. Marshall Hunt, Horizon's CEO, said: "We are excited about this opportunity which demonstrates our dedication to the oncology market with a significant expansion to our product line. We are pleased to expand our relationship with Medtronic, and are proud that our investment in developing a superior sales organization can be more fully utilized." "This collaboration reflects Medtronic's commitment to oncology by providing dedicated nationwide coverage for our HAI therapy," added Carol Barnett, Vice President and General Manager of Medtronic Global Pain. According to the American Cancer Society, more than 140,000 people are diagnosed annually with colorectal cancer. Despite treatment, approximately 60% of these patients will experience liver metastases. Several studies have demonstrated the efficacy of hepatic arterial infusion (HAI) in the treatment of hepatic metastases. These studies show a significant advantage in tumor response with regional Continue reading >>

Subscribe To Read

Subscribe To Read

Subscribe to the FT to read: Financial Times Medtronic sells supplies unit to Cardinal Health for $6.1bn Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust. Choose the subscription that is right for you Not sure which package to choose? Try full access for 4 weeks For 4 weeks receive unlimited Premium digital access to the FT's trusted, award-winning business news Purchase a Standard Digital subscription. Be informed with the essential news and opinion MyFT track the topics most important to you FT Weekend full access to the weekend content Mobile & Tablet Apps download to read on the go Gift Article share up to 10 articles a month with family, friends and colleagues All the essentials plus deeper insights and analysis In-depth analysis on trade, emerging markets, M&A, investing and more ePaper a digital replica of the newspaper Gift Article share up to 20 articles a month with family, friends and colleagues Purchase a Premium Digital + Newspaper subscription. FT Newspaper delivered daily plus unlimited digital access Continue reading >>

How Medtronic Makes Money

How Medtronic Makes Money

If you were starting a business from scratch with the intention of it going global, you could do worse than zeroing in on medical devices. The industry featurescustomer base numbers in the hundreds of millions, and almost all the purchasing is done via thirdparties. Medtronic( MDT ), the $108billion Dublin/Minneapolis-based global entity, exemplifies the industry, selling medical devices in 160 countries while turning a profit of $4billion on revenues of $29.7billion in 2017. Medtronics four major reporting segments according to its latest annual reportare cardiac and vascular; minimally invasive therapies; restorative therapies; and diabetes. Cardiac and vascular accounted for$10.5billion of salesin fiscal year 2017. The cardio and vascular operations are further divided into subgroups that manage the following types of diseases: cardiac rhythm and heart failure; coronary and structural heart; and aortic and peripheral vascular. The cardiac and vascular division makes, among many other devices, pacemakers and defibrillators. The cost of traditional pacemakers average $2,500, according to the Alliance of Cardiovascular Professionals, while a defibrillatorcan run about $2,000. Almost always its going to be an insurer or medical provider thats footing the bill. Other heart products in the Medtronic line include cryoballoons, which freeze heart tissue thats responsible for irregular beats. Such devices are prohibitively expensive for personal use, although it's highly unlikely that a patient with an irregular heartbeat would be administering their own cryoballoon anyway. Instead the devices are sold to hospitalsenabling thousands of patients to be treated. Medtronic makes other devices that would have been the stuff of science fiction to the eyes of the companys nineteent Continue reading >>

About Medtronic Ecr Journal

About Medtronic Ecr Journal

European Cardiovascular Disease 2006 - Issue 1;2006:2(1):1-1 Medtronic is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people worldwide. With deep roots in the treatment of heart disease, Medtronic now provides a wide range of products and therapies - every six seconds, somewhere in the world, a persons life is saved or improved by a Medtronic product or therapy. Medtronic was founded on 29 April 1949 in Minneapolis, Minnesota, US, by Earl E Bakken and Palmer J Hermundslie. Medtronic Cardiac Rhythm Management (CRM) develops products that restore and regulate a patients heart rhythm, as well as improve the hearts pumping function. The business markets implantable pacemakers, defibrillators, cardiac ablation catheters, monitoring and diagnostic devices and cardiac resynchronisation devices, including the first implantable device for the treatment of heart failure. In addition, the business markets automated external defibrillators (AEDs) - which are increasingly being placed in public places, such as businesses, airports, shopping centres and even homes - and the CareLink Patient Network, the industrys first Internet-based network to enable physicians to remotely monitor their patients who have cardiac devices. Medtronic Cardiac Surgery develops products that are used in both arrested and beating heart bypass surgery. The business also markets the industrys broadest line of heart valve products for replacement and repair, plus autotransfusion equipment and disposable devices for handling and monitoring blood during major surgery, as well as cardiac ablation devices to treat a variety of heart conditions. Medtronic Vascular offers products and therapies that treat a wide range of vascular diseases and con Continue reading >>

Medtronic Plc (mdt.n) Company Profile | Reuters.com

Medtronic Plc (mdt.n) Company Profile | Reuters.com

Medtronic Public Limited Company (Medtronic), incorporated on June 12, 2014, is a medical technology, services and solutions company. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes cardiac rhythm and heart failure, coronary and structural heart, and aortic and peripheral vascular. Its Minimally Invasive Therapies Group segment includes surgical solutions, and patient monitoring and recovery. Its Restorative Therapies Group segment includes spine, neuromodulation, surgical technologies and neurovascular. Its Diabetes Group segment includes intensive insulin management, non-intensive diabetes therapies, and diabetes services and solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc. The Company's Cardiac Rhythm & Heart Failure Disease Management (CRHF) division develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failure. Its products include implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRHF devices and an integrated health solutions business. The Company's Implantable Cardiac Pacemakers (Pacemakers) include Advisa MRI SureScan models, the Micra Transcatheter Pacing System and the Ensura MRI SureScan model. Its Implantable Cardioverter Defibrillators (ICDs) include Evera MRI SureScan. The Company's Implantable Cardiac Resynchronization Therapy Devices (CRT-Ds and CRT-Ps) consist of CRT-Ds, which include Amplia/Compia/Claria family of MRI Quad CR Continue reading >>

Medtronic, Inc.|company Profile|vault.com

Medtronic, Inc.|company Profile|vault.com

Sometimes the best medicine is a short, sharp shock; that's why Medtronic's products reside in its customers' hearts and minds (among other places). A leading maker of implantable biomedical devices, the company makes defibrillators and pacemakers that issue electrical impulses or shocks to keep hearts beating normally. Its Cardiac and Vascular Group also produces catheters, stents, valves, balloons, and surgical ablation technologies used to treat vascular and heart disease. The company's Restorative Therapies Group makes nerve and brain stimulation devices, implantable drug delivery systems, products used to manage diabetes, and surgical devices for ear, nose, and throat (ENT) and spinal conditions. Medtronic got its start treating heart disease -- it was a leader in the development of pacemakers in the 1950s -- and a majority of its revenue still comes from sales of products used to treat heart or vascular conditions. However, it has expanded its reach into the rest of the human body, and the rest of the world, by offering products that treat neurological, musculoskeletal, and metabolic conditions as well. Within the Cardiac and Vascular Group, which accounts for about half of revenue, reside its Cardiac Rhythm & Heart Failure Disease Management (CRHF), Coronary & Structural Heart Disease Management (CSH), and Aortic & Peripheral Vascular Disease Management divisions. CRHF is Medtronic's largest single unit, accounting for about 25% of sales; the unit makes pacemakers, defibrillators, heart monitors, and other products used to keep the heart beating properly. The remaining Cardiac and Vascular units focus on minimally invasive technologies including drug-eluting stents to prevent reclogging of arteries (Coronary division) and aortic heart valves (Structural Heart), Continue reading >>

Cardinal Health To Acquire Leading Patient Product Portfolio From Medtronic For $6.1 Billion - Apr 18, 2017

Cardinal Health To Acquire Leading Patient Product Portfolio From Medtronic For $6.1 Billion - Apr 18, 2017

Cardinal Health to Acquire Leading Patient Product Portfolio from Medtronic for $6.1 Billion - Increases Cardinal Health's product breadth in consumable medical products - Creates additional geographic scale and scope and expands existing channel reach into the operating room and long-term care DUBLIN, Ohio, April 18, 2017 / PRNewswire / --Cardinal Health (NYSE: CAH) today announced that it has entered into a definitive agreement to acquire Medtronic's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash. The purchase price does not include cash tax benefits of at least $100 million. The acquisition is expected to be financed with a combination of $4.5 billion in new senior unsecured notes and existing cash. The transaction is expected to close in the first quarter of Cardinal Health's fiscal year 2018, subject to customary closing conditions, including regulatory clearances. The Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses encompass 23 product categories across multiple market settings, including numerous industry-leading brands, such as Curity, Kendall, Dover, Argyle and Kangaroo, which are used in nearly every U.S. hospital. Total revenues for the businesses were $2.3 billion for the 12 months ending October 2016 with more than 70 percent of total sales in the U.S. Cardinal Health expects the acquisition to be accretive to non-GAAP1 diluted earnings per share from continuing operations by more than$0.21per share in fiscal 2018, which includes approximately $100 million of inventory step-up costs during the first few quarters following closing. This is net of estimated incremental annual financing-related interest expense of up to $0.39, subject to change based on the company's ultimate bo Continue reading >>

Cardinal Health To Acquire Portion Of Medtronics Patient Monitoring & Recovery Division For $6.1b

Cardinal Health To Acquire Portion Of Medtronics Patient Monitoring & Recovery Division For $6.1b

April 19, 2017 8:39 AM | By Andrea Gonzalez | No comments yet Medtronic plc is set to sell its patient care, deep vein thrombosis and nutritional insufficiency businesses within the Patient Monitoring & Recovery (PMR) division of its Minimally Invasive Therapies Group to Dublin, Ohio-based Cardinal Health Inc. for $6.1 billion. The transaction could close sometime by the end of Medtronics second fiscal quarter in October. Combined, the businesses expected to be divested in the transaction generated about $2.4 billion in revenue over the last four reported quarters. Among the product lines included in the transaction are the companys dental/animal health, chart paper, wound care, incontinence, electrodes, Sharpsafety, thermometry, perinatal protection, blood collection, compression, and enteral feeding offerings. The transaction also will include 17 dedicated manufacturing facilities. Dublin-based Medtronic will retain its Respiratory & Monitoring Solutions business, which includes its airway, ventilators, monitors, sensors and health informatics product lines, as well as its Renal Care Solutions business, both of which are within its PMR division. Medtronic obtained much of the PMR division when its $43 billion acquisition of Covidien plc closed in 2015. (See Medical Device Daily, Jan. 27, 2015.) Ultimately, we came to the conclusion that these products while truly meaningful to patients in need are best suited under ownership that can provide the investment and focus that these businesses require, said Omar Ishrak, Medtronics president and CEO. At the same time, we can put these proceeds to work, investing over the long-term in higher returning internal and external opportunities that are more directly aligned with our growth strategies of therapy innovation, globaliz Continue reading >>

Cardinal Health (nyse:cah) Buying Medtronic (nyse: Mdt) Product Lines For $6.1 Billion - Minneapolis / St. Paul Business Journal

Cardinal Health (nyse:cah) Buying Medtronic (nyse: Mdt) Product Lines For $6.1 Billion - Minneapolis / St. Paul Business Journal

Editor in chief, Columbus Business First Cardinal Health Inc. is buying several medical product lines from Medtronic for $6.1 billion in cash. In the deal with the medical-device giant, Dublin-based Cardinal (NYSE:CAH) has agreed to buy Medtronic's patient care, deep vein thrombosis and nutritional insufficiency lines. The company said the lines include 23 product categories and several well-established brands used in nearly every U.S. hospital, including Curity, Kendall, Dover, Argyle and Kangaroo. The deal had been suspected; Medtronic was reported to be in talks with Cardinal earlier this month . "We are thrilled about today's announcement, as this well-established product line is complementary to our medical consumables business and fits naturally into our customer offering. For this reason, this product portfolio has been on our radar for many years," Cardinal CEO George Barrett said in a press release . "We distribute some of these products today and have been collaborative partners with the leadership of this business," he said. "Given the current trends in health care, including aging demographics and a focus on post-acute care, this industry-leading portfolio will help us further expand our scope in the operating room, in long-term care facilities and in home health care, reaching customers across the entire continuum of care." The deal means more than 10,000 employees will become part of Cardinal Health, already one of the region's largest employers . It wasn't immediately clear how many workers may move to Dublin, if any. Medtronic (NYSE: MDT) is based in Dublin, Ireland, and its operational headquarters are in Fridley, Minnesota. The Metronic product lines brought in $2.3 billion in revenue in the year ended in October, with more than 70 percent of those sa Continue reading >>

Cytori - Macropore Biosurgery Sells Assets For

Cytori - Macropore Biosurgery Sells Assets For "bioresorbable Craniofacial/ Neurosurgical Fixation" Product Line To Medtronic For $21 Million; Spine Implant Products Co-development Agreement Extended To 2012

MacroPore Biosurgery Sells Assets for "Bioresorbable Craniofacial/ Neurosurgical Fixation" Product Line To Medtronic for $21 Million; Spine Implant Products Co-development agreement extended to 2012 San Diego, October 1st, 2002 - MacroPore Biosurgery, Inc. (Frankfurt Stock Exchange: XMP) announced today that Medtronic, Inc. (NYSE: MDT) has purchased all assets of the Craniofacial/Neurosurgical (CMF/N) fixation product line of MacroPore Biosurgery. In a second transaction, Medtronic and MacroPore extended the term of an ongoing global co-development and supply agreement for spinal implants to 2012. The asset acquisition, valued at up to $21 million, will be paid in cash. In addition to the initial payment of $13 million, there are three milestone payments totaling up to $8 million, which are estimated to occur during 2003. In a separate transaction, MacroPore Biosurgery agreed to pay Medtronic $4 million for a waiver on the first rights to distribute the MacroPore TS product line in certain markets. Medtronic has been distributing the CMF/N product line since January 2000 through its Neurological Technology division. Issuer's information/explanatory remarks concerning this Ad Hoc announcement: "Our nearly three-year partnership with Medtronic has allowed more doctors and patients to recognize the benefits of our CMF/N products," said Christopher J. Calhoun, President / CEO of MacroPore Biosurgery. "This is a natural next step for both companies that allows us to focus on what we do best and delivers an important product for Medtronic in a $300 million global market." "By selling this product line to Medtronic, we accomplish three things," explains Mr. Calhoun. "First, we streamline operations and lower operating costs. Second, we will increase our focus on emerging mark Continue reading >>

5. Medtronic Spine - Covering The Specialized Field Of Orthopedic Product Development And Manufacturing

5. Medtronic Spine - Covering The Specialized Field Of Orthopedic Product Development And Manufacturing

Karen L. Parkhill, Exec. VP and Chief Financial Officer Gary L. Ellis, Exec. VP of Global Operations and Information Technology Bradley E. Lerman, Sr. VP, General Counsel and Corporate Secretary Geoffrey S. Martha, Exec. VP and President, Restorative Therapies Group Robert ten Hoedt, Exec. VP and President, EMEA One of the most beloved movie endings ever filmed almost never made it onscreen. The script for the 1971 musical fantasy Willy Wonka and the Chocolate Factory originally ended with Grandpa Joe shouting, Yippie! and then fading to black. But Emmy award-winning director Mel Stuart wanted a better closing line, and reportedly phoned writer David Seltzer from the set to request a more memorable finale. Seltzer could only come up with one idea, though it was a bit clich. In the films final scenecherished by millions of fans worldwidethe eccentric title character announces he is giving his entire factory to Charlie Bucket, a kind-hearted, honest, but poor boy who lives with his widowed mother and four bedridden grandparents in the slums of an unnamed European city. As Charlies disbelief turns to gratitude, Wonka hugs the boy, then tells him, But Charlie, dont forget what happened to the man who suddenly got everything he always wanted. He lived happily ever after, Wonka replies, smiling. Of course he did. It is a movie, after all. Hollywood is notorious for its happy endings, but such closure is not as readily found off-screen. Fairy tales and their all-is-well finales are pure fiction; the real world doesnt work that wayits cold, inconsistent, and oftentimes unfair. It offers no guarantees on contentment. Joy can be particularly elusive in business, even for companies that follow Wonkas guide to eternal euphoria. Apple Inc.s Cinderella-like evolution, for example, s Continue reading >>

More in diabetes